NeuraLight, an Israeli medtech startup that offers a solution to help provide teleneurology with smartphones, raised $5.5 million in Seed funding co-led by MSAD.vc, Kli Capital, and Tuesday Capital. With this raise, NeuraLight comes out of stealth.
The company was founded this year by Micha Breakstone, who co-founded Chorus.ai, a sales platform based on natural language processing and enables the extraction of insights from sales staff discussions in order to boost their chances of success. In July that company had a big exit when it sold to ZoomInfo for $575 million in cash.
Teleneurology is a form of Telemedicine that enables neurology to be practiced when the doctor and patient are not present in the same place, and possibly not at the same time.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Neurology.org explains that Telemedicine is a mode of delivery for clinical neurology established as a standard model in stroke systems of care, when considering the use of technology to increase access to care, stroke is the perfect paradigm in the acute setting, allowing us to bring the doctor to the patient for rapid evaluation and treatment decisions. Impact on clinical outcomes is easily evaluated in telestroke, and there is a measurable impact on public health, including increased tissue plasminogen activator delivery and development of stroke units, particularly in low-resource areas without full-time neurology coverage.
NeuraLight declares that it is building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders using information captured with a standard smartphone or webcam.
The company explains that neurological screening, diagnosis, and care are highly subjective and dependent on manual examination with multiple signs and symptoms that are non-trivial to elicit or detect.
So, how does NeuraLight help to solve this? It says that its AI-driven platform automatically extracts micro-oculometrics, providing objective and sensitive digital markers for neurological disorders. The company promises to serve as a robust proxy for currently used endpoints, and ultimately define a new measurement standard, paving the path for precision medicine in neurology.
“Neurological diseases are slow killers and are notoriously difficult to measure and treat, so often patients and their loved ones are at the mercy of the disease and it’s painful to watch,” said NeuraLight’s CEO and Co-Founder Dr. Micha Breakstone. “We are on a mission to help improve the quality of life for patients suffering from neurological disorders, and we’re doing that by giving pharmaceutical companies tools to find neurological patterns in patients during clinical trials and build more targeted and effective therapies.”